108 related articles for article (PubMed ID: 1382494)
1. Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours.
Schöber C; Schmoll E; Schmoll HJ; Poliwoda H; Schuppert F; Stahl M; Bokemeyer C; Wilke H; Weiss J
Eur J Cancer; 1992; 28A(10):1664-6. PubMed ID: 1382494
[TBL] [Abstract][Full Text] [Related]
2. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
Biesma B; Willemse PH; Mulder NH; Verschueren RC; Kema IP; de Bruijn HW; Postmus PE; Sleijfer DT; de Vries EG
Br J Cancer; 1992 Nov; 66(5):850-5. PubMed ID: 1384643
[TBL] [Abstract][Full Text] [Related]
3. Recombinant alpha-2b interferon in patients with malignant carcinoid tumour.
Basser RL; Lieschke GJ; Sheridan WP; Fox RM; Green MD
Aust N Z J Med; 1991 Dec; 21(6):875-8. PubMed ID: 1726359
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.
Bajetta E; Zilembo N; Di Bartolomeo M; Di Leo A; Pilotti S; Bochicchio AM; Castellani R; Buzzoni R; Celio L; Dogliotti L
Cancer; 1993 Nov; 72(10):3099-105. PubMed ID: 7693327
[TBL] [Abstract][Full Text] [Related]
5. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?
Välimäki M; Järvinen H; Salmela P; Sane T; Sjöblom SM; Pelkonen R
Cancer; 1991 Feb; 67(3):547-9. PubMed ID: 1702352
[TBL] [Abstract][Full Text] [Related]
6. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
[TBL] [Abstract][Full Text] [Related]
7. A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour.
Veenhof CH; de Wit R; Taal BG; Dirix LY; Wagstaff J; Hensen A; Huldij AC; Bakker PJ
Eur J Cancer; 1992; 28(1):75-8. PubMed ID: 1373635
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors.
Saltz L; Kemeny N; Schwartz G; Kelsen D
Cancer; 1994 Aug; 74(3):958-61. PubMed ID: 8039124
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic carcinoid tumour with recombinant interferon alfa.
Joensuu H; Kumpulainen E; Gröhn P
Eur J Cancer; 1992; 28A(10):1650-3. PubMed ID: 1382493
[TBL] [Abstract][Full Text] [Related]
10. Treatment of carcinoid syndrome with recombinant interferon alpha-2a.
Di Bartolomeo M; Bajetta E; Zilembo N; de Braud F; Di Leo A; Verusio C; D'Aprile M; Scanni A; Barduagni M; Barduagni A [corrected to Barduagni M]
Acta Oncol; 1993; 32(2):235-8. PubMed ID: 7686766
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study.
Jacobsen MB; Hanssen LE; Kolmannskog F; Schrumpf E; Vatn MH; Bergan A
Scand J Gastroenterol; 1995 Aug; 30(8):789-96. PubMed ID: 7481548
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of metastasized carcinoid tumor of the ileum and cecum with recombinant alpha-2b interferon].
Doberauer C; Niederle N; Kloke O; Kurschel E; Schmidt CG
Onkologie; 1987 Dec; 10(6):340-4. PubMed ID: 2450326
[TBL] [Abstract][Full Text] [Related]
13. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide.
Creutzfeldt W; Bartsch HH; Jacubaschke U; Stöckmann F
Acta Oncol; 1991; 30(4):529-35. PubMed ID: 1713038
[TBL] [Abstract][Full Text] [Related]
14. Expression of p68 protein kinase and its prognostic significance during IFN-alpha therapy in patients with carcinoid tumours.
Zhou Y; Gobl A; Wang S; Jacobsen MB; Janson ET; Haines GK; Radosevich JA; Oberg K
Eur J Cancer; 1998 Dec; 34(13):2046-52. PubMed ID: 10070309
[TBL] [Abstract][Full Text] [Related]
15. Extended experience with recombinant alpha-2b interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumours. A preliminary report.
Hanssen LE; Schrumpf E; Jacobsen MB; Kolbenstvedt AN; Kolmannskog F; Bergan A; Dolva LO
Acta Oncol; 1991; 30(4):523-7. PubMed ID: 1854510
[TBL] [Abstract][Full Text] [Related]
16. Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors.
Zilembo N; Buzzoni R; Bajetta E; Di Bartolomeo M; de Braud F; Castellani R; Maffioli L; Celio L; Villa E; Lorusso V
Acta Oncol; 1993; 32(2):245-50. PubMed ID: 8391833
[TBL] [Abstract][Full Text] [Related]
17. Diagnosing, treating and managing carcinoid tumours.
Burgess A
Nurs Times; 2005 Jul 19-25; 101(29):32-4. PubMed ID: 16052941
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
[TBL] [Abstract][Full Text] [Related]
19. Recombinant alpha-2 interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumours. A preliminary report.
Hanssen LE; Schrumpf E; Kolbenstvedt AN; Tausjø J; Dolva LO
Acta Oncol; 1989; 28(3):439-43. PubMed ID: 2742781
[TBL] [Abstract][Full Text] [Related]
20. Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide.
Joensuu H; Kätkä K; Kujari H
Acta Endocrinol (Copenh); 1992 Feb; 126(2):184-5. PubMed ID: 1371898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
